The ESMO Immuno-Oncology Congress 2020 programme is now online!
- Update your knowledge in the fast-developing field of cancer immunotherapy
- Understand what is in progress with other immune-related pathways beyond immune check-point inhibitors
- Review the current state-of-the-art in immunotherapy for the most frequent cancers
- Learn how to best use immunotherapy strategy in combination with other anti-cancer treatments
ESMO-MORA: The Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.
The Congress webcasts will include all the sessions of the official programme, where speaker permission is granted, and will be available on the page dedicated to meeting resources on this website and OncologyPRO for ESMO members.